Publications by authors named "Concepcion Prats"
Article Synopsis
- - The addition of molecular data to prognostic models has improved the risk assessment of low-risk myelodysplastic neoplasms (LR-MDS), but the specific impact of molecular lesions in this group remains uncertain.
- - In a study of 227 LR-MDS patients, RUNX1 mutations were linked to lower overall survival, while SF3B1 mutations showed a reduced risk of death; both TP53 and RUNX1 mutations were also predictive of leukaemic progression.
- - The traditional measure of blast percentage did not significantly affect survival or progression probabilities in LR-MDS patients when molecular data was included, highlighting its decreased clinical relevance in this context.
Introduction: Prognosis of patients with myelodysplastic syndrome (MDS), particularly the group with lower-risk disease (LR-MDS) is very heterogeneous. Several studies have described the prognostic value of recurrent somatic mutations in MDS including all risk categories. Recently, the incorporation of genomic data to clinical parameters defined the new Molecular International Prognostic Scoring System (IPSS-M).
View Article and Find Full Text PDFHematopoietic progenitor cells (HPCs) from granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood (G-PB), bone marrow (BM), or umbilical cord blood (CB) have differing biological properties and differing kinetics of engraftment post-transplantation, which might be explained, at least in part, by differing gene and miRNA expression patterns. To assess the differences in gene and miRNA expression, we analyzed whole genome expression profiles as well as the expression of 384 miRNAs in CD34(+) cells isolated from 18 healthy individuals (6 individuals per subtype of HPC source). We identified 43 genes and 36 miRNAs differentially expressed in the various CD34(+) cell sources.
View Article and Find Full Text PDFGranulocyte colony-stimulating factor is the most commonly used cytokine for the mobilization of hematopoietic progenitor cells from healthy donors for allogeneic stem cell transplantation. Although the administration of this cytokine is considered safe, knowledge about its long-term effects, especially in hematopoietic progenitor cells, is limited. On this background, the aim of our study was to analyze whether or not granulocyte colony-stimulating factor induces changes in gene and microRNA expression profiles in hematopoietic progenitor cells from healthy donors, and to determine whether or not these changes persist in the long-term.
View Article and Find Full Text PDFObjective: To correlate blood coagulation factor levels with disease severity in cirrhotic patients evaluated as candidates for liver transplantation.
Material And Method: We included 87 patients (75.9% men) with a mean age of 54+/-9.